A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)

a study on Colorectal Cancer Pancreatic Ductal Adenocarcinoma Biliary Tract Cancer Gastrointestinal Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:

  • About the safety and how well people tolerate sacituzumab tirumotecan alone or with chemotherapy
  • How many people have the cancer respond (get smaller or go away) to treatment

Official Title

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Keywords

Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer, Biliary Tract Neoplasms, Gastrointestinal Neoplasms, Leucovorin, Fluorouracil, Levoleucovorin, Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Sacituzumab tirumotecan + Chemotherapy

Eligibility

You can join if…

Open to people ages 18 years and up

The main inclusion criteria include but are not limited to the following:

You CAN'T join if...

The main exclusion criteria include but are not limited to the following:

  • History of severe eye disease
  • Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Locations

  • UCLA ( Site 0317) accepting new patients
    Los Angeles California 90095 United States
  • University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293) accepting new patients
    Madison Wisconsin 53792 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Merck Sharp & Dohme LLC
Links
Merck Clinical Trials Information Plain Language Summary
ID
NCT06428409
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 130 study participants
Last Updated